Introduction {#S0001}
============

Lung cancer has become the most common malignant tumor worldwide, with high mortality.[@CIT0001] In 2016, the epidemiological data from the USA displayed that the incidence and mortality rates of lung cancer were 57.3/100,000 and 46.0/100,000, respectively, and the newly diagnosed cases and estimated deaths were 224,390 and 158,050, respectively.[@CIT0002] Non-small cell lung cancer (NSCLC) comprised approximately 85% of all lung cancers and numerous patients with NSCLC at diagnosis already had metastatic disease.[@CIT0002],[@CIT0003]Figure 1Flow chart of the meta-analysis selection process.

Recently, the discovery of immune checkpoint inhibitors has led to a step forward in the treatment of advanced NSCLCs. Immune checkpoints such as PD-1/L1 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) were considered as the main brakes of T cell immune response, creating a comfortable microenvironment for tumor growth and assisting tumor escape from the body's immune response.[@CIT0004],[@CIT0005] Many tumor cells are capable of upregulating the expression of PD-L1, which results in the inability of cytotoxic T cells after ligand binding to PD-1.[@CIT0006]--[@CIT0008] Therefore, blockade of the PD-1 pathway with monoclonal antibodies against PD-1 or PD-L1 can improve the body's immune response against tumor cells.[@CIT0009] Indeed, immune checkpoint inhibitors achieved unprecedented antitumor efficacy, in particular, PD-1/L1 inhibitors.[@CIT0010]--[@CIT0015] In 2015 and 2016, the FDA approved 3 immune checkpoint inhibitors (anti-PD-1 antibodies: nivolumab, pembrolizumab; anti-PD-L1 antibodies: atezolizumab) for the therapy of patients with metastatic NSCLC who have progressed on from first-line platinum-based doublet chemotherapy.[@CIT0016]--[@CIT0018] In late 2016, the US Food and Drug Administration (FDA) further approved pembrolizumab for the first-line therapy for patients with advanced non-squamous or squamous NSCLC.[@CIT0019] However, primary resistance to anti-PD-1/L1 antibody was commonly observed.[@CIT0020] Under this circumstance, it is difficult to achieve a long-lasting antitumor efficacy with single-agent monotherapy, which only covers a small population of patients. To enhance clinical benefits of immunotherapy for NSCLC patients, anti-PD-1/L1 antibodies are being evaluated in combination with CTLA-4 inhibitors, chemotherapeutic agents, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), indoleamine-2,3-dioxygenase (IDO) inhibitors, etc. A series of phase I/II studies on NSCLC have confirmed the efficacy of combination therapy.[@CIT0021]--[@CIT0024] However, most of those trials were performed without comparable forms, and usually as a single arm. Considering the small samples of these studies, therefore, we made a timely summarization by quantitative meta-analysis, in which all available evidence was incorporated to evaluate the efficacy and safety of PD-1/L1 inhibitors combination therapy including anti-CTLA-4 antibody, chemotherapy, EGFR-TKIs and IDO inhibitors on NSCLC patients.

Methods {#S0002}
=======

Search strategy {#S0002-S2001}
---------------

This meta-analysis was performed in accordance with Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines. We searched PubMed, the Cochrane Library and the Embase database up to July 2018, for randomized clinical trials (RCTs) which including the combination therapy with the anti-PD-1/L1 MoAb for advanced NSCLC patients. The following search terms were used: "nivolumab" OR "opdivo" OR "ONO-4538" OR "BMS-936558" OR "MDX-1106" "atezolizumab" OR "Tecentriq" OR "MPDL-3280A" OR "RG-7446" OR "pembrolizumab" OR "Keytruda" OR "lambrolizumab" OR "MK-3475" OR "PEMBRO" OR "durvalumab" OR "MEDI-4736" OR "Imfinzi" OR "pidilizumab" OR "CT-011" OR "PD-1" OR "PD-L1" OR "PD-1/PD-L1" OR "programmed cell death 1" OR "programmed cell death ligand 1" and "NSCLC" OR "non-small-cell lung cancer" OR "non-small-cell lung carcinoma" and combined OR combination. We also reviewed the relevant abstracts from the American Society of Clinical Oncology (ASCO), World Conference on Lung Cancer (WCLC) and European Society of Medical Oncology (ESMO). We also searched the ClinicalTrials.Gov website (<https://clinicaltrials.gov>) to find ongoing studies and unpublished data.

Selection criteria {#S0002-S2002}
------------------

The inclusion criteria for the eligible studies were as follows: I) patients who were histologically diagnosed with advanced NSCLC; II) studies reporting the combination therapy of anti-PD1/L1 antibody with CTLA-4 inhibitors/chemotherapy/EGFR-TKIs/IDO inhibitors; III) studies with available primary outcome (objective response rate: ORR); IV) studies published in English. In the event that studies with multiple follow-ups over time, we only reported the most up-to-date data. Studies failing to meet the inclusion criteria would be excluded in the current meta-analysis.

Data extraction {#S0002-S2003}
---------------

The work of data extraction and assessment was done by two different authors (Ning Wan and Bo Ji) independently, and discrepancies were further discussed with the third author (Tiantian Zhang) to reach consensus. For each clinical trial, the information of the first author, year of publication, number of patients, ORR, PFS, OS and safety outcomes including rate of Grade 3--Grade 5 drug-related adverse effects (G3-5 DRAEs), pneumonitis and drug-related death was recorded.

### Risk of bias within studies {#S0002-S2003-S3001}

Risks of bias within studies without comparable arms were assessed using the methodological item for non-randomized studies (MINORS) reported by Slim.[@CIT0025] The Cochrane Risk of Bias tool was used for the randomized controlled trials. The study quality was assessed by two reviewers (Ning Wan and Bo Ji) independently, and the assessments were verified by the third reviewer (Chen Yang).

### Statistic analysis {#S0002-S2003-S3002}

The pooled data of ORR, 6-month progression-free survival rate (6m PFSr), 1-year overall survival rate (1y OSr), G3--G5 DRAEs, pneumonitis, and drug-related death rate were obtained by Stata version 14.0 (Stata A Corp, College Station, TX, USA). In addition, ORR were further stratified depending on the PD-L1 expression status of the tumor. Since the definition of PD-L1 positivity was different in clinical trials,[@CIT0019] we selected PD-L1≥1% as a cutoff to identify PD-L1 positive patients in our studies according to the literature.[@CIT0026] The heterogeneity of the extracted data was evaluated by *I*^2^ statistic and chi-square Q test, in which *I*^2^≥50% (for the *I*^2^ statistic) or *P*≤0.05 (for the Q test) was considered significant heterogeneity. Random-effects model was applied under the circumstance of high potential heterogeneity, to avoid underestimating the standard errors of pooled data.

### Assessment of publication bias {#S0002-S2003-S3003}

Funnel plot, Egger linear regression test, and Begg rank correlation method were applied to determine publication bias.

Results {#S0003}
=======

Search results {#S0003-S2001}
--------------

As shown in [Figure 1](#SF0001), a total of 1,505 records were yielded through the search strategy, which identified 271 articles in PubMed, 171 articles in the Cochrane Library, and 1,063 articles in the Embase database. Finally, 17 studies[@CIT0021]-[@CIT0024],[@CIT0027]--[@CIT0039] published in English were enrolled for meta-analysis according to the selection criteria, which involved 1,222 NSCLC patients.

Characteristics of included studies {#S0003-S2002}
-----------------------------------

Among these 17 studies, 6 studies[@CIT0021],[@CIT0027]--[@CIT0031] reported the efficacy and toxicities of anti-PD-1/L1 antibody in combination with anti-CTLA-4 antibody therapy for the treatment of advanced NSCLC, and 384 patients were enrolled. Six studies[@CIT0022],[@CIT0032]--[@CIT0036] involved research into the combination therapy of anti-PD-1/L1 antibody and chemotherapy involving 700 patients. Four studies[@CIT0023],[@CIT0037]--[@CIT0039] reported the combination therapy of anti-PD-1/L1 antibody with EGFR-TKIs, and 95 patients were enrolled. One study[@CIT0024] reported the combination of pembrolizumab with epacadostat involving 43 patients. The ORR across the studies varied from 16.3% to 79%. The median follow-up duration varied from 6.7 to 19 months. Only 5 studies were available to determine the 6m PFSr, and 6 studies were available to extract the 1yOSr. In these 17 studies, only 3 studies[@CIT0022],[@CIT0030],[@CIT0033] were performed with control groups; others were performed as a single arm or multiple arms. The detailed characteristics of the enrolled studies are summarized in [Table 1](#T0001){ref-type="table"}.Table 1Characteristics of included studies for meta-analysisReferencesTrials number/namePhaseMedian follow up duration (months)No. of participantsNSCLC stagePrevious treatmentInterventionPD-L1 TPSORR (%)6m PFSr1y OSr**Anti-PD-1/L1 antibody therapy in combination with anti-CTLA-4 antibody**Patnaik \[2015\][@CIT0027]NCT02039674INA11IIIB/IV≤2 prior regimensPembro+\
IpiNATotal: 6/11 (54.5%)NANAGubens \[2016\][@CIT0028]NCT02039674I/II745Advanced NSCLC≥1 prior regimenPembro+\
Ipi＜1% n=21\
≥1% n=24≥50%n=6Total: 11/45 (24.4%) PD-L1 Expression ＜1% 4/21 (19.0%) ≥1% 7/24 (29.2%) ≥50% 1/6 (16.7%)NANAAntonia \[2014\][@CIT0031]CheckMate 012I6.7--10.8 (across 4 cohorts)49Advanced NSCLC.Chemo- naiveNivo+Ipi＜5% n=22≥5% n=16Total: 8/49 (16.3%)\
PD-L1 Expression\
＜5% 3/22 (13.6%)\
≥5% 3/16 (18.8%)17/49 (34.7%)NAHellmann \[2017\][@CIT0021]NCT01454102/CheckMate 012I11·8--12.8 (across 2 cohorts)77IIIb/IVChemo- naiveNivo+Ipi＜1% n=19≥1% n=46\
≥50%n=13Total: 33/77 (42.8%)\
PD-L1 Expression\
＜1% 4/19 (21%)\
≥1% 26/46 (57%)\
≥50%12/13 (92%)NA59/77 (76.6%)Hellmann \[2018\][@CIT0030]NCT02477826/CheckMate 227III11.2139IV or recurrentChemo- naiveNivo+Ipi＜1% n=38\
≥1% n=101Total: 63/139(45.3%)\* 59/139(42.6%)43/139(30.9%)Antonia \[2016\][@CIT0029]NCT02000947Ib4.763Advanced or metastatic NSCLCnone/≥1 prior regimenDurva+\
Treme≥25% n=18 ＜25% n=37 0% n=24 unknown n=8Total: 11/63 (17.5%) PD-L1 Expression ≥25%: 4/18 (22.2%)\
＜25%: 6/37 (16.2%)\
0%: 5/24 (20.8%)\
unknown: 1/8 (12.5%)NANA**Anti-PD-1/L1 antibody therapy in combination with chemotherapy**Gadgeel \[2016\][@CIT0032]NCT02039674/KEYNOTE-021I1274Advanced NSCLCChemo- naivePembro+ Chemo＜1% n=22≥1% n=51\
≥50% n=25Total: 42/74 (56.8%) PD-L1 Expression ＜1% 12/22 (55%)\
≥1% 29/51 (57%)\
≥50%15/25 (60%)NANALanger \[2016\][@CIT0033]NCT02039674/KEYNOTE-021II10.660IIIB/IVChemo- naivePembro+ Chemo＜1% n=21≥1% n=39\
≥50%n=25Total:34/60 (57%)\
＜1% 12/21 (57%) ≥1% 21/39 (54%)\
≥50% 16/25 (80%)46/60 (76.7%)46/60 (76.7%)Gandhi \[2018\][@CIT0022]NCT02578680III10.5410Metastatic NSCLCnonePembro+ Chemo＜1% n=127; ≥1% n=260;\
unknown‖n=23;Total: 195/410 (47.6%)\
＜1% 41/127 (32%)\
≥1% 143/260 (55%)\*140/410 (34.1%)284/410 (69.2%)Kanda \[2016\][@CIT0034](JapicCTI)-132,071Ib3.19--9.43 (across 4 arms).24IIIB/IV, or recurrent NSCLCnone/≥1 prior regimenNivo+ ChemoNATotal: 13/23 (56.5%)14/24 (58.3%)NALiu \[2015\][@CIT0035]NCT01633970IbNA76Advanced or metastatic NSCLC.Chemo- naiveAtezo+ ChemoNATotal: 37/76 (49%)NANARizvi \[2016\][@CIT0036]NCT01454102I1956IIIB/IV NSCLCChemo- naiveNivo+ Chemo＜1% n=21; ≥1% n=23; unknown n=12;Total: 24/56 (43%) PD-L1 Expression ＜1% 9/21 (43%) ≥1% 11/23 (48%) unknown 4/12 (33%)30/56 (53.6%)40/56(71.4%)**Anti-PD-1/L1 antibody therapy in combination with EGFR-TKIs**Rizvi \[2014\][@CIT0037]\_I1821IIIB/IVChemo- naiveNivo+ ENATotal: 4/21 (19%)11/21 (52.4%)15/21 (71.4%)Gibbons \[2016\][@CIT0023]NCT02088112INA20EGFR mutant NSCLCTKI- naiveDurva+GNATotal: 15/19 (79%)NANAMa \[2016\][@CIT0038]NCT02013219I11.220Advanced NSCLCNAAtezo+ ENATotal: 15/20 (75%)NANAAhn \[2016\][@CIT0039]NCT02143466IbNA34EGFR mutant NSCLCnone/≥1 prior regimenDurva+ONATotal: 16/33 (48%)NANA**Anti-PD-1/L1 antibody therapy in combination with IDO inhibitors**Gangadhar \[2017\][@CIT0024]ECHO202/KEYNOTE-037I/IINA43Advanced NSCLC≤2 prior regimenPembro+Epa＜50% n=17; ≥50% n=7;Total: 14/40 (35%) PD-L1 Expression ＜50% 6/17 (35%)\
≥50% 3/7 (43%)NANA[^2]

Risk of bias in individual studies {#S0003-S2003}
----------------------------------

The risks of bias within the 17 studies included in the current study are summarized in [Tables S1](#ST0001) and [S2](#ST0002).

Meta-analysis results of anti-PD-1/L1 antibody combination therapy {#S0003-S2004}
------------------------------------------------------------------

### Pooled ORR {#S0003-S2004-S3001}

ORR data were extracted from 17 studies for meta-analysis to assess the efficacy of combination regimens. The pooled ORR was 44% (95% CI: 36--52%) and the random effects model was applied as significant heterogeneity was detected (*I*^2^=86.0% *P*\<0.001, [Figure 2](#F0002){ref-type="fig"}). We then performed a subgroup analysis of the combination regimens, dividing into four groups: anti-PD-1/L1 antibody combination therapy with anti-CTLA-4 antibody/chemotherapy/EGFR-TKIs/IDO inhibitors for NSCLC patients. The combined ORR values were 32% (95% CI: 19--44%), 49% (95% CI: 46--53%), 55% (95% CI: 28--83%) and 35% (95% CI: 20--50%) respectively ([Figure 3](#F0003){ref-type="fig"}).Figure 2Forest plot of the pooled overall response rate (ORR) of anti-PD-1/L1 antibody combination therapy for NSCLC patients.**Abbreviation:** NSCLC, non-small cell lung cancer.Figure 3Forest plots of the subgroup analyses of the combination therapy of anti-PD-1/L1 antibody and anti-CTLA-4 antibody/chemotherapy/EGFR-TKIs/IDO inhibitors for NSCLC patients.**Abbreviation:** NSCLC, non-small cell lung cancer.

#### Pooled ORR of combination therapy for first/second or more line therapy {#S0003-S2004-S3001-S4001}

A total of 11 eligible trials[@CIT0021],[@CIT0022],[@CIT0030]--[@CIT0037],[@CIT0039] involving 990 patients were included to evaluate the efficacy of anti-PD-1/L1 antibody combination therapy in the first-line setting for NSCLC patients, and the ORRs ranged from 16% to 70%. As there was no study reporting the combination therapy of PD-1/L1 inhibitors with IDO inhibitors in the first line setting, we only evaluated PD-1/L1 inhibitor combination therapy with the 3 other therapeutic regimens. A random-effect model was performed to evaluate the pooled ORR with high heterogeneity (*I*^2^=81.7%; *P*\<0.001). The combined ORR was 45.0% (95% CI: 37--53%, [Figure 4A](#F0004){ref-type="fig"}). The pooled ORR of anti-PD-1/L1 antibody combination therapy with anti-CTLA-4 antibody/chemotherapy/EGFR-TKIs in the first-line setting for NSCLC patients was 35% (95% CI: 17--53%), 51% (95% CI: 46--56%) and 43% (−7--93%) respectively ([Figure 4A](#F0004){ref-type="fig"}). A total of 5 eligible trials[@CIT0024],[@CIT0027],[@CIT0028],[@CIT0034],[@CIT0039] involving 125 patients were included to evaluate the efficacy of anti-PD-1/L1 antibody combination therapy in the second or more line setting for NSCLC patients, and the ORR ranged from 17% to 55%. The combined ORR was 32.0% (95% CI: 23--42%) ([Figure 4B](#F0004){ref-type="fig"}). The pooled ORR of anti-PD-1/L1 antibody combination therapy with anti-CTLA-4 antibody/chemotherapy/EGFR-TKIs/IDO inhibitors in the second or more line setting for NSCLC patients was 36% (95% CI: 8--65%), 17% (95% CI: −13--46%), 39% (95% CI:19--59%) and 35% (95% CI:20--50%), respectively ([Figure 4B](#F0004){ref-type="fig"}).Figure 4Forest plot of the pooled overall response rate (ORR) of anti-PD-1/L1 antibody combination therapy as a first line treatment (**A**) and as second or more line treatment for NSCLC patients (**B**).**Abbreviation:** NSCLC, non-small cell lung cancer.

#### PD-L1 positive versus negative {#S0003-S2004-S3001-S4002}

Nine studies without the ORR data correlated with PD-L1 expression status were excluded in the related analysis. As we selected PD-L1≥1% as a cutoff to identify PD-L1 positive patients, studies[@CIT0024],[@CIT0029],[@CIT0031] reporting other PD-L1 expression levels were excluded. Five studies[@CIT0021],[@CIT0028],[@CIT0032],[@CIT0033],[@CIT0036] with 287 patients assessed the ORR correlated with the tumor PD-L1 expression status. Among 183 patients with PD-L1 expression positive status (≥1% of expression), the ORR was 50% (95% CI: 40--60%, [Figure 5A](#F0005){ref-type="fig"}). The pooled ORR of anti-PD-1/L1 antibody combination therapy with anti-CTLA-4 antibody/chemotherapy was 43% (95% CI: 17--70%)/54% (95% CI: 45--63%) respectively ([Figure 5A](#F0005){ref-type="fig"}). Among 104 patients with PD-L1 expression negative status (\<1% of expression), the ORR was 38% (95% CI: 22--54%, [Figure 5B](#F0005){ref-type="fig"}). The pooled ORR of anti-PD-1/L1 antibody combination therapy with anti-CTLA-4 antibody/chemotherapy was 20% (95% CI: 8--32%)/52% (95% CI: 39--64%) respectively ([Figure 5B](#F0005){ref-type="fig"}).Figure 5Forest plot of the pooled overall response rate (ORR) of anti-PD-1/L1 antibody combination therapy for PD-L1 expression positive (**A**) and negative (**B**) NSCLC patients.**Abbreviation:** NSCLC, non-small cell lung cancer.

The pooled ORR of combination therapy involving PD-1/L1 inhibitors was similar in PD-L1 positive and negative NSCLC patients (OR=0.67, 95% CI: 0.38--1.20, [Figure 6](#F0006){ref-type="fig"}). For the patients receiving anti-PD-1/L1 therapy combination therapy with anti-CTLA-4 antibody, patients with PD-L1 positive status exhibited a superior ORR than those with PD-L1 negative status (OR=0.33, 95% CI: 0.12--0.88, [Figure 6](#F0006){ref-type="fig"}). For the patients receiving combination therapy of anti-PD-1/L1 therapy with chemotherapy, patients with PD-L1 positive status showed a similar ORR with those in PD-L1 negative status (OR=0.96, 95% CI: 0.51--1.78, [Figure 6](#F0006){ref-type="fig"}).Figure 6Meta-analysis of the associations between overall response rate (ORR) and programmed death-ligand 1 (PD-L1) expression.

### Pooled 6m PFSr and 1y OSr {#S0003-S2004-S3002}

6m PFSr data were extracted from 4 studies[@CIT0031],[@CIT0033],[@CIT0034],[@CIT0036] for meta-analysis. The pooled 6m PFSr was 55% (95% CI: 31--80%), and a random effects model was applied as significant heterogeneity was detected (*I*^2^=91.6% *P*\<0.001, [Figure 7A](#F0007){ref-type="fig"}). We then performed a subgroup analysis of the combination regimens, dividing into two groups: anti-PD-1/L1 antibody combination therapy with anti-CTLA-4 antibody/chemotherapy for NSCLC patients. The combined ORR values were 35% (95% CI: 21--48%), 63%(95%Cl: 47%-80%) respectively ([Figure 7A](#F0007){ref-type="fig"}). The 1y OSr data were extracted from 4 studies[@CIT0022],[@CIT0030],[@CIT0033],[@CIT0036] for meta-analysis. The pooled 1y OSr was 62% (95% CI: 41--83%), and a random effects model was applied due to the significant heterogeneity (*I*^2^=96.4% *P*\<0.001, [Figure 7B](#F0007){ref-type="fig"}). The subgroup analysis of the combination regimens achieved an ORR 31% (95% CI: 23--39%) with anti-CTLA-4 antibody, and 70% (95% CI: 67--74%) with chemotherapy ([Figure 7B](#F0007){ref-type="fig"}).Figure 7Forest plot of the pooled 6m PFSr (**A**) and 1y OSr (**B**) of anti-PD-1/L1 antibody combination therapy for NSCLC patients.**Abbreviations:** 6m PFSr, 6-month progression-free survival rate; 1y OSr, 1-year overall survival rate.

### Adverse effects {#S0003-S2004-S3003}

Adverse effects including the rate of G3-5 DRAEs, pneumonitis and drug-related deaths are recorded in [Table 2](#T0002){ref-type="table"}. Data of G3-5 DRAEs rate were not available in 4 studies,[@CIT0022],[@CIT0023],[@CIT0034],[@CIT0035] pneumonitis (≥G3) rate was not available in 3 studies,[@CIT0028],[@CIT0032],[@CIT0039] and drug-related death rates were not available in 5 studies,[@CIT0023],[@CIT0024],[@CIT0035],[@CIT0037],[@CIT0038] so that these studies were excluded in the correlated meta-analysis. A meta-analysis of the safety outcomes from different combination regimens is exhibited in [Table 3](#T0003){ref-type="table"}. Here, we concluded the combination regimens that have data available, in fact, a large number of ongoing clinical trials are investigating these regimens for NSCLC patients. A summary of ongoing clinical trials enrolling NSCLC patients for the combination therapy of anti-PD1/L1 antibody with other treatments, including anti-CTLA-4 antibody, chemotherapy, targeted therapy or IDO inhibitors other immunotherapies, and chemotherapy, is presented in [Table 4](#T0004){ref-type="table"}.Table 2Safety outcomes of the included studiesStudy （Reference）G3--5 DRAEsPneumonitis (≥G3)Drug-related deathPatnaik \[2015\][@CIT0026]2/17 (11.8%)0/170Gubens \[2016\][@CIT0027]11/45 (24.4%)NA1Antonia \[2014\][@CIT0031]24/49 (49.0%)3/493Hellmann \[2017\][@CIT0021]20/77 (26.0%)3/770Hellmann \[2018\][@CIT0030]180/576(31.2%)13/5767Antonia \[2016\][@CIT0029]43/102 (42.2%)4/993Gadgeel \[2016\][@CIT0032]30/74 (40.5%)NA1Langer \[2016\][@CIT0033]23/60 (38.3%)1/601Gandhi \[2018\][@CIT0022]NA11/41027Kanda \[2016\][@CIT0034]NA1/240Rizvi \[2016\][@CIT0036]25/56 (44.6%)4/560Liu \[2015\][@CIT0035]NA0/76NAGettinger \[2014\][@CIT0037]5/21 (23.8%)0/21NAGibbons \[2016\][@CIT0023]NA1/20NAMa \[2016\][@CIT0038]8/20 (40.0%)0/20NAAhn \[2016\][@CIT0039]20/34 (58.8%)NA0Gangadhar \[2017\][@CIT0024]7/43 (16.3%)4/43NA[^3] Table 3Meta-analysis of rate of G3-5 DRAEs, pneumonitis and drug-related death in combination therapyCombination regimensItems for evaluationRate (%)95% CIAnti-PD-1/L1 antibody therapy in combination with ipilimumab (IPI)Rate of G3--5 DRAEs3123--39%Rate of pneumonitis32--4%Rate of drug-related death11--2%Anti-PD-1/L1 antibody therapy in combination with chemotherapyRate of G3--5 DRAEs4134--48%Rate of pneumonitis21--3%Drug-related death30--5%Anti-PD-1/L1 antibody therapy in combination with EGFR-TKIsRate of G3--5 DRAEs4120--62%Rate of pneumonitis3−1--7%Drug-related death1−3--6%Anti-PD-1/L1 antibody therapy in combination with IDO inhibitorsRate of G3--5 DRAEs165--27%Rate of pneumonitis91--18%Drug-related death\-- Table 4Ongoing clinical trials of anti-PD-1/L1therapy combination therapy for NSCLC patientsClinical Trials. Gov numberTrial namePhasePathology or histologyAgentsCombination with anti-CTLA-4 antibodyNCT02659059CheckMate568IITreatment-naive, metastatic NSCLCNivolumab+ ipilimumabNCT02864251CheckMate722IIIEGFR mutation, T790M negative NSCLCNivolumab vs nivolumab+ ipilimumab vs carboplatin/pemetrexedNCT02352948ARCTICIIIPreviously treated NSCLCDurvalumab±tremelimumab vs SOCNCT02542293NEPTUNEIIITreatment-naive,stage IV NSCLCDurvalumab±tremelimumab vs SOCNCT02453282MYSTICIIITreatment-naive, stage IV NSCLCDurvalumab±tremelimumab vs SOCCombination with chemotherapyNCT02477826CheckMate227IIITreatment naive, metastatic or recurrent NSCLCNivolumab+ PT-DCNCT01840579KEYNOTE-011IAdvanced NSCLC (stage III B/IV)Pembrolizumab+PT-DC or ipilimumabNCT02775435KEYNOTE407IIIMetastatic,squamous cell NSCLC (first line)Pembrolizumab +carboplatin/Nab -paclitaxel (or paclitaxel)NCT02366143IMpower 150IIITreatment-naïve NSCLC, non squamous cell histologyAtezolizumab + PT-DC therapy with or without bevacizumabNCT02657434IMpower132IIIChemotherapy-naive, stage IV, non squamous cell NSCLCAtezolizumab +carboplatin or cisplatin/pemetrexedNCT02367794IMpower 131IIIStage IV squamous NSCLCAtezolizumb + carboplatin/nab-paclitaxel (or paclitaxel)NCT02367781IMpower 130IIIStage IV Non-Squamous NSCLCAtezolizumb + carboplatin/nab- paclitaxelCombination with targeted therapyNCT02039674KEYNOTE-021I/IIStage IIIb/IV NSCLCCohort E and F: Pembrolizumab+ erlotinib or gefitinibNCT02364609--IEGFR mutant after resistance to EGFR TKI NSCLCPembrolizumab + afatinibNCT02574078CheckMate370I/IIEGFR/ALK mutant treatment\
naïve NSCLCNivolumab + erlotinib or crizotinibNCT02393625--IALK mutant NSCLCNivolumab+ ceritinibNCT02511184KEYNOTE-050IALK mutant treatment naïve NSCLCPembrolizumab + crizotinibNCT02584634Javelin Lung 101I/IIALK mutant or not NSCLCAvelumab+Lorlatinib or crizotinibNCT02323126--IIEGFR mutant or MET positive\
NSCLCNivolumab+EGF816 or capmatinibNCT02898116--I/IIALK mutant NSCLCDurvalumab + ensartinibNCT01998126_IStage IV NSCLC, failed prior platinum-based therapyNivolumab + erlotinib (EGFR mutant) or crizotinib (ALK mutant)NCT01454102CheckMate012IStage IIIB/IV (NSCLC)Cohort D: nivolumab + bevacizumab maintenanceNCT02574078CheckMate370I/IILocally advanced or stage IV NSCLCNivolumab + bevacizumab or pemetrexed maintenanceNCT02681549--IINon-squamous NSCLCPembrolizumab + bevacizumabNCT02443324--INonsquamous or squamous NSCLCPembrolizumab + RamucirumabCombination with IDO inhibitorsNCT02298153ECHO-110IAdvanced NSCLC and urothelial carcinomaAtezolizumab+ epacadostatNCT02327078ECHO-204I/IISCCHN and NSCLCNivolumab+ epacadostatNCT03322566ECHO-306/KEYNOTE-715IIImNSCLCPembrolizumab+epacadostat\
with or without platinum-based chemotherapyNCT03322540ECHO-305/KEYNOTE-654IIImNSCLC with high PD-L1 levelsPembrolizumab+epacadostat[^4]

### Sensitivity analysis {#S0003-S2004-S3004}

In order to detect how the uncertain factors impacted the final results, a sensitivity analysis was performed in the current study. The sensitivity analysis indicated that none of the single studies would significantly affect the results of PD-1/L1 inhibitor combination therapy (data not shown).

Publication bias {#S0003-S2005}
----------------

A funnel plot analysis of the studies of PD-1/L1 inhibitor combination therapy indicated an asymmetric distribution ([Figure S1](#SF0001)); the Egger linear regression test (*t*=3.67, *P*=0.002) verified that there was potential publication bias ([Figure S2](#F0002){ref-type="fig"}). However, the Begg rank correlation method (*z*=−0.16, *P*=0.869) indicated there was no publication bias ([Figure S3](#F0003){ref-type="fig"}). As Egger's linear regression method was reported to have stronger statistical and discriminatory powers than Begg's method for detecting publication bias[@CIT0040] and combining the results of the funnel plot, we identified that there was potential publication bias in the current study. One possible reason is the small sample size of trials.

Discussion {#S0004}
==========

The current meta-analysis observed that the combination therapy involving PD-1/L1 inhibitors with other therapeutic regimens (including CTLA-4 inhibitors, chemotherapy, EGFR-TKIs and IDO inhibitors) demonstrated promising efficacy and tolerable safety profile. We also found that combination therapy of PD-1/L1 inhibitors with CTLA-4 inhibitors exhibits potent efficacy to PD-L1 positive patients. Meanwhile, for patients receiving combination therapy of PD-1/L1 inhibitors with chemotherapy, it showed similar efficacy in PD-L1 positive or negative patients.

Xu et al[@CIT0041] performed a meta-analysis to investigate potential treatment strategies using combinations of PD-1/L1 inhibitors with chemotherapy or other CTLA4 inhibitors in the first-line setting for lung cancer patients. In our meta-analysis, we focused on the combination regimens of PD-1/L1 inhibitors for NSCLC patients. To supplement this, we updated the data of combinations of PD-1/L1 inhibitors with chemotherapy or CTLA4 inhibitors, and the combination of PD-1/L1 inhibitors with EGFR-TKIs or IDO inhibitors was also included. In addition, the first line and second or more line settings for NSCLC patients were analyzed in the current meta-analysis. More importantly, we further evaluated the impact of PD-L1 status on combination therapy of PD-1/L1 inhibitors with CTLA-4 inhibitors or chemotherapy.

Oncogenic alteration in the EGFR pathway is related to the induction of PD-L1 expression and makes lung tumors susceptible to PD-1 blockade in a preclinical model,[@CIT0042] which demonstrated that a combination of EGFR TKIs with PD-1/L1 inhibitors might be a promising therapeutic regimen to prolong the duration of response and prevent or delay resistance.[@CIT0043] In the current meta-analysis, we pooled the available data for combination therapy of PD-1/L1 inhibitors with EGFR TKIs for NSCLC patients. IDO is an enzyme mediating cleavage of tryptocan to kynurenine. High expression of IDO often leads to an immunosuppressive tumor microenvironment, which increased the differentiation of regulatory T (Treg) cells, impaired the activity of effector T cells, and decreased the functions of dendritic cells.[@CIT0044] It was reported IDO inhibitors had synergistic antitumor effects in melanoma models with immune checkpoint inhibitors.[@CIT0045] These preclinical data establish a strong foundation for exploration of clinical combination therapy of PD-1/L1 inhibitors with IDO inhibitors. Therefore, in the current meta-analysis, we also pooled the available data for combination therapy of PD-1/L1 inhibitors with IDO inhibitors for NSCLC patients.

The pooled ORR of the combination regimens of PD-1/L1 inhibitors for NSCLC patients was 44% in our meta-analysis. As there was significant heterogeneity, we then performed a subgroup analysis of the combination regimens for NSCLC patients. The combined ORR for first line PD-1/L1 inhibitors, in combination with CTLA-4 inhibitors and chemotherapy were 35% and 51%, respectively, which was consistent with previous results[@CIT0041] However, one of the included studies for combination therapy of PD-1/L1 with inhibitors in their meta-analysis enrolled patients who had received ≥2 prior lines (55%).[@CIT0029] In the current study, the ORR of combination therapy for the second or more line setting was also evaluated. It worth noting that the ORR of PD-1/L1 combination therapy with chemotherapy or EGFR-TKIs in the second or more line setting decreased compared with that in the first line setting. This might be partly associated with the reason that monotherapy of PD-1/L1 inhibitors achieved lower efficacy in the second or more line setting for NSCLC patients.[@CIT0046]

In the subgroup analysis, the pooled 6m PFSr and 1y OSr for combination therapy of PD-1/L1 with CTLA-4 or chemotherapy were 35% or 65% (6m PFSr) and 31% or 70% (1y OSr), respectively. The results were in line with the study[@CIT0041] of the combination therapy of PD-1/L1 inhibitors and chemotherapy, while the results were not available for the combination therapy of PD-1/L1 inhibitors and CTLA-4 inhibitors in Xu's study.

PD-L1 expression in immune cells and tumor cells has become a biomarker which can assist in decision-making in clinical treatment strategies.[@CIT0047] Nearly 50% of NSCLC patients are reported to have high expression of PD-L1, and this may result in poor prognosis.[@CIT0048] Wang et al[@CIT0049] and Zhang et al[@CIT0050] found that NSCLC patients exhibited poor OS with positive PD-L1 expression. Our result showed that the pooled ORR of combination therapy of PD-1/L1 inhibitors for PD-L1 positive or negative NSCLC patients had no significant difference. As for subgroup analysis, anti-PD-1/L1 drugs combined with anti-CTLA-4 drugs exhibited a more potent efficacy on patients with high expression of PD-L1. This trend was not observed in patients receiving combination therapy of PD-1/L1 inhibitors and chemotherapy. As was reported in a recent phase III study, the efficacy of nivolumab was uncorrelated with PD-L1 expression in squamous-cell NSCLC.[@CIT0011] In our study, we did not report the related outcome for NSCLC patients with different histologies due to the limitation of RCTs, which may account for the results in our study to some extent.

Despite the impressive response rates of immune checkpoint inhibitors, they can contribute to both unique and severe toxicities.[@CIT0051]--[@CIT0053] In the current meta-analysis, the results showed that the combined strategies were relatively safe and remained tolerable.

The use of the PD-1/L1 inhibitors had been reported to correlate with the development of severe pneumonitis which had resulted in drug-related deaths in clinical trials.[@CIT0011]--[@CIT0013],[@CIT0015] Hence we also assessed the rate of pneumonitis in the combination regimens. The combination of PD-1/L1 inhibitors with IDO inhibitors showed a relatively high rate of pneumonitis. As for the rate of drug-related death, the four combination regimens were almost the same.

Despite the data of combination regimens discussed in the meta-analysis, plenty of clinical trials are ongoing. The ongoing clinical trials for combination therapy of PD-1/L1 inhibitors with CTLA-4 inhibitors, chemotherapy, EGFR-TKIs, and IDO inhibitors are described in [Table 1](#T0001){ref-type="table"}. Recently, a phase III RCT, named the MYSTIC study (NCT02453282), failed to fulfill its primary endpoint. The strategy of durvalumab combined with tremelimumab (CTLA-4 inhibitors) failed to prolong PFS compared with chemotherapy in NSCLC patients with PD-L1 expression\>25%. The recent results of CheckMate370 (NCT02574078), a phase II/III RCT, were promulgated.[@CIT0054] Thirteen patients were treated with nivolumab plus crizotinib, and 5 patients (38%) discontinued the combination therapy due to severe hepatic toxicities. Two of the 5 patients died, which might be caused by the presence of severe hepatic toxicities. Enrollment for combination therapy was closed, and the treatment strategy discontinued due to severe hepatic toxicities (Grade≥3). Only 5 patients (38%) had a partial response. Overall, the results of the study do not support further assessment of the current combination regimens.

There are several limitations to the current meta-analysis. Firstly, most of the included studies in the meta-analysis were performed without comparable arms, and some of them only had a very small sample size. Even so, large numbers of studies focusing on PD-1/L1 inhibitors in combination with other agents are ongoing, and we will update the meta-analysis in the future. Secondly, the definition of PD-L1 positive status varied in the recent studies, and the optimal cutoff value for PD-L1 positive status is controversial. Hence, to identify a specific biomarker for anti-PD-1/L1 therapy becomes imperative. Thirdly, we have not distinguished the impact of histology subtype of NSCLC (squamous or non-squamous) on the efficacy of combination therapy, due to the limitation of included trials. Additionally, we did not analyze the PFS and OS due to limitations of the included data, and a potential impact of selection bias and publication bias existed. Finally, compared with a traditional meta-analysis, the pooled single arm meta-analysis was not yet mature.

Conclusion {#S0005}
==========

In summary, the four combination regimens involving PD-1/L1 inhibitors with CTLA-4 inhibitors, chemotherapy, EGFR-TKIs and IDO inhibitors were potential treatment strategies and well tolerated for NSCLC patients. Further, the therapy lines and PD-L1 expression status were correlated with treatment efficacy.
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[^2]: **Note:** \*1-year progression-free survival rate.

    **Abbreviations:** ORR, objective response rate; 6m PFSr, 6-month progression-free survival rate; 1y OSr, 1-year overall survival rate; TPS, tumor proportion score; NA, not available; Chemo, chemotherapy; Pembro, pembrolizumab; Ipi, ipilimumab; Nivo, nivolumab; Durva, durvalumab; Treme, tremelimumab; Atezo, atezolizumab; E, erlotinib; G, geﬁtinib; O, osimertinib; Epa, epacadostat.

[^3]: **Abbreviations:** G3--5 DRAEs, Grade 3--Grade 5 drug-related adverse effects; NA, not available.

[^4]: **Abbreviations:** NSCLC, non--small cell lung cancer; PT-DC, platinum doublet chemotherapy; SOC, standard of care; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; SCCHN, squamous cell carcinoma of head and neck; mNSCLC, metastatic non--small cell lung cancer.
